A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter

Inclusion Criteria:

• Diagnosed with and candidate for clinically-indicated cardiac ablation procedure forthe management of ventricular tachycardia, premature ventricular complex,scar-related atrial tachycardia or atrial fibrillation (participants havingundergone a previous ablation procedure may be included)

• Signed participants Informed Consent Form (ICF)

• Able and willing to comply with all pre-, post-, and follow-up testing andrequirements

Exclusion Criteria:

• Structural heart defect which can only be repaired by cardiac surgery

• Pericarditis within 6 months

• Left ventricular ejection fraction (LVEF) less than or equal to (<=) 25 percent (%)for ventricular tachycardia (VT) participants

• LVEF <= 40% for participants with atrial arrhythmia

• History of chronic gastro-intestinal medical problems involving the esophagus,stomach and/or untreated acid reflux

• History of abnormal bleeding and/or clotting disorder

• Clinically significant infection or sepsis

• History of stroke or transient ischemic attack (TIA) within the past 6 months ofenrollment

• Uncontrolled heart failure or New York Heart Association (NYHA) function class IV

• Implanted with a pacemaker or intracardiac cardiac defibrillator within the past 6weeks (42 days)

• Implanted with a mechanical valve

• Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or otherabnormality that precludes catheter introduction or manipulation

• Any of the following within 6 months of enrollment: major surgery except for theindex procedure, myocardial infarction, unstable angina, percutaneous coronaryintervention

• Participants with any other significant uncontrolled or unstable medical condition (such as uncontrolled bradyarrhythmia's, ventricular arrhythmias, hyperthyroidism,or significant coagulation disorder)

• Significant congenital anomaly or medical problem that in the opinion of theinvestigator would preclude enrollment in this study

• Women who are pregnant (as evidenced by pregnancy test if pre-menopausal),lactating, or who are of childbearing age and plan on becoming pregnant during thecourse of the clinical investigation

• Categorized as vulnerable population and requires special treatment with respect tosafeguards of well-being

• Concurrent enrollment in an investigational study evaluating another device or drug